Doctor's Bio
Mehmet Asim Bilen, MD, serves as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bilen joined the clinical staff at Grady’s Cancer Center as a practicing physician in July 2016. He is actively involved in clinical research and patient care in the area of genitourinary cancers. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Grady Clinical Research Committee. Dr. Bilen holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: Hacettepe University Medical School
- Internship: Baylor College of Medicine
- Residency: Baylor College of Medicine
Fellowships
University of Texas MD Anderson Cancer Center
Locations and Directions
Correll Pavilion
Phone: (404) 616-1000
Location:
80 Gilmer St. SE
Atlanta, GA 30303
Publications
- Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
Saeed F, Berchuck JE, Bilen MA, Gandhi JS, Nazha B, Brown JT, Schuster DM, Jani AB, Yu J, Harik LR
Cancer. 2025;131(16):e70037.
PMID: 40782341 - Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M
European urology focus. 2025;
PMID: 40738794 - Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A
Clinical cancer research : an official journal of the American Association for Cancer Research. 2025;
PMID: 40689871 - Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).
Bilen MA, Lowentritt B, Burbage S, Kinkead F, Khilfeh I, Rossi C, Du S, Wong G, Pilon D, Joshi K, Shore ND
Journal of medical economics. 2025;28(1):1096-1109.
PMID: 40660892 - Somatic yolk sac tumors in the urinary tract: A form of rare divergent differentiation.
Tedrow N, Ogan K, Joshi S, Bilen MA, Brown J, Carthon B, Saeed F, Gandhi J, Genega E, Harik L
Human pathology. 2025;
PMID: 40578489 - REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens.
Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, Bilen MA, Buch D, Chang M, Chin E, Darabi S, Dhanikonda N, Ghatalia P, Grigg CM, Grier AL, Jindal T, Jung J, Kilari D, Kumar HLS, Lee S, Neelands B, Pandya C, Pawalek J, Staggers J, Yildirim A, Zakharia Y, Zarrabi KK, Zimmerman M, Sledge G, Spetzler D, Elliott A, McKay RR, Barata PC
The oncologist. 2025;
PMID: 40536267 - Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies.
Yildirim A, Moses MW, Gerke M, Jani Y, Thompson JC, Akova U, Bilen MA
Therapeutic advances in medical oncology. 2025;
PMID: 40535735 - Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer.
Bilen MA, Burbage S, Rossi C, Khilfeh I, Diaz L, Wang Y, Pilon D, Brown G, Shore N, Lowentritt B, Lin DW
Advances in therapy. 2025;42(8):3945-3959.
PMID: 40528125 - Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.
Bilen MA, Lowentritt B, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND
Advances in therapy. 2025;42(7):3437-3454.
PMID: 40439959 - Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.
Lowentritt B, Bilen MA, Khilfeh I, Rossi C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L, Shore ND
Journal of comparative effectiveness research. 2025;14(7):e250023.
PMID: 40340441
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.